share_log

Barclays Maintains Equal-Weight on BioCryst Pharma, Raises Price Target to $7

Benzinga ·  Aug 6, 2024 08:53  · Ratings

Barclays analyst Gena Wang maintains BioCryst Pharma (NASDAQ:BCRX) with a Equal-Weight and raises the price target from $6 to $7.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment